B Braun Company Profile

What is the competitive landscape for B BRAUN

B BRAUN has one hundred and eighteen approved drugs.

There are two US patents protecting B BRAUN drugs.

There are twenty-seven patent family members on B BRAUN drugs in twenty-seven countries and two hundred and thirty-nine supplementary protection certificates in sixteen countries.

Summary for B Braun

International Patents:	27
US Patents:	2
Tradenames:	226
Ingredients:	64
NDAs:	118

Drugs and US Patents for B Braun

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	MANNITOL 10%	mannitol	INJECTABLE;INJECTION	016080-002	Approved Prior to Jan 1, 1982		DISCN	No	No
B Braun	GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	gentamicin sulfate	INJECTABLE;INJECTION	062814-003	Aug 28, 1987		DISCN	No	No
B Braun	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	dextrose; sodium chloride	INJECTABLE;INJECTION	018376-001	Approved Prior to Jan 1, 1982		DISCN	No	No
B Braun	RINGER'S IN PLASTIC CONTAINER	calcium chloride; potassium chloride; sodium chloride	INJECTABLE;INJECTION	018721-001	Nov 9, 1982		DISCN	No	No
B Braun	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	dextrose; sodium chloride	INJECTABLE;INJECTION	019631-009	Feb 24, 1988	AP	RX	No	No
B Braun	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	dextrose; potassium chloride; sodium chloride	INJECTABLE;INJECTION	019630-004	Feb 17, 1988		RX	No	No
B Braun	FREAMINE III 3% W/ ELECTROLYTES	amino acids; magnesium acetate; phosphoric acid; potassium chloride; sodium acetate; sodium chloride	INJECTABLE;INJECTION	016822-003	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for B Braun

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
B Braun	HEPATAMINE 8%	amino acids	INJECTABLE;INJECTION	018676-001	Aug 3, 1982	3,950,529
B Braun	UCEPHAN	sodium benzoate; sodium phenylacetate	SOLUTION;ORAL	019530-001	Dec 23, 1987	4,284,647

International Patents for B Braun Drugs

Country	Patent Number	Estimated Expiration
Croatia	P20131221
Malaysia	180957
South Africa	201504618
China	105283222
European Patent Office	1931304
Spain	2441790
Denmark	1931304

Supplementary Protection Certificates for B Braun Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2957286	300962	Netherlands		PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170721
1307486	SPC/GB12/030	United Kingdom		PRODUCT NAME: CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)), PASIREOTIDE, OR SALTS THEREOF; REGISTERED: UK EU/1/12/753/001-012 20120424
0328535	96C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
2340828	C202130003	Spain		PRODUCT NAME: SACUBITRILO/VALSARTAN, COMO COMPLEJO SALINO DE SACUBITRILO, VALSARTAN Y SODIO, ES DECIR (((S)-N-VALERIL-N-((2'-(1H-TETRAZOL-5-IL)-BIFENIL-4-IL)-METIL)-VALINA) / ESTER ETILICO DEL ACIDO ((2R,4S)-5-BIFENIL-4-IL-4-(3-CARBOXI-PROPIONIL AMINO)-2-METIL-PENTANOICO)) NA3 - X H2O, EN EL QUE X ES 0 A 3; NATIONAL AUTHORISATION NUMBER: EU/1/15/1058; DATE OF AUTHORISATION: 20151119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1058; DATE OF FIRST AUTHORISATION IN EEA: 20151119
0748228	SPC/GB11/004	United Kingdom		PRODUCT NAME: MANNITOL; REGISTERED: SE 22708 20061020; UK PL 27944/0001-0001 20071218
2603514	2019/018	Ireland		PRODUCT NAME: A COMBINATION OF VABORBACTAM, AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE; REGISTRATION NO/DATE: EU/1/18/1334 20181120
1713823	92595	Luxembourg		PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• B Braun
• B Braun Medical Inc

B. Braun: A Pharmaceutical Powerhouse - Market Position, Strengths & Strategic Insights

In the ever-evolving landscape of the pharmaceutical industry, B. Braun stands as a beacon of innovation and reliability. This German medical and pharmaceutical device company has carved out a significant niche for itself, becoming a global leader in healthcare solutions. Let's dive deep into B. Braun's market position, strengths, and strategic insights that have propelled it to the forefront of the industry.

The B. Braun Legacy

Founded in 1839, B. Braun has a rich history spanning over 180 years. What started as a small pharmacy in Melsungen, Germany, has grown into a multinational corporation with a presence in over 60 countries. This longevity is a testament to the company's ability to adapt and innovate in the face of changing healthcare needs.

A Family-Owned Giant

One of the unique aspects of B. Braun is that it remains a family-owned business, despite its massive global footprint. This structure allows for long-term strategic planning and a consistent corporate culture, which are often challenging to maintain in publicly traded companies.

Market Position and Global Reach

B. Braun's market position is formidable, with a diverse portfolio of over 5,000 healthcare products[1]. The company's global presence is impressive, with offices and production facilities in more than 60 countries[1]. This extensive network allows B. Braun to respond quickly to local market needs while maintaining a global perspective.

Revenue and Growth

In 2023, B. Braun reported sales of €8.75 billion, representing a 3% increase from the previous year[9]. This growth, achieved in an uncertain market environment, underscores the company's resilience and strategic acumen.

"Despite an uncertain market environment, B. Braun sales increased 3 percent to € 8.75 billion in 2023."[9]

Core Strengths and Competitive Advantages

Diverse Product Portfolio

B. Braun's product range is vast and varied, covering numerous medical disciplines. From intravenous solutions and infusion pumps to surgical instruments and wound management products, the company offers comprehensive solutions for healthcare providers[1].

Manufacturing Excellence

A key strength of B. Braun is its manufacturing capabilities. The company produces 95% of its products in-house, ensuring quality control and supply chain stability[1]. This vertical integration is a significant competitive advantage, especially in times of global supply chain disruptions.

Focus on Innovation

Innovation is at the heart of B. Braun's strategy. The company invests heavily in research and development, continuously introducing new products and improving existing ones. For instance, the development of the Onvision Needle Tip Tracking system has solidified B. Braun's position as a world leader in regional anesthesia[3].

Strong Hospital Care Division

B. Braun's Hospital Care division is particularly noteworthy, being a leading supplier for infusion, nutrition, and pain therapy[3]. The division's comprehensive portfolio, including advanced systems like the B. Braun Suite software solution, sets it apart in the market.

Strategic Insights

Emphasis on Digitalization

B. Braun has recognized the importance of digital transformation in healthcare. The company is focusing on digitalizing its services, developing cloud platforms, and exploring the Internet of Medical Things (IoMT)[3]. This forward-thinking approach positions B. Braun at the forefront of healthcare technology.

Expansion through Partnerships

B. Braun has been strategic in forming partnerships to drive innovation and expand its reach. For example, in 2017, the company entered into an alliance with Philips in the field of ultrasound-guided regional anesthesia[1]. Such collaborations allow B. Braun to leverage external expertise and resources, accelerating its growth and innovation.

Investment in U.S. Manufacturing

Recognizing the importance of supply chain resilience, B. Braun has invested over $1 billion in new and expanded North American pharmaceutical manufacturing facilities[7]. This investment not only ensures a more reliable supply of vital products but also strengthens the company's position in the crucial U.S. market.

Market Challenges and Responses

Supply Chain Disruptions

Like many global companies, B. Braun has faced challenges due to supply chain disruptions, particularly during the COVID-19 pandemic. However, the company's strategy of increasing "safety stock" inventory levels has helped mitigate these issues[7].

Competitive Landscape

The pharmaceutical and medical device industry is highly competitive. B. Braun faces competition from other global giants as well as innovative startups. To maintain its edge, the company focuses on continuous innovation, quality improvement, and strategic acquisitions.

Future Outlook and Growth Opportunities

Telehealth and Remote Patient Monitoring

As healthcare increasingly moves towards digital and remote solutions, B. Braun is well-positioned to capitalize on this trend. The company's focus on developing and expanding telehealth facilities presents significant growth opportunities[3].

Emerging Markets

While B. Braun has a strong presence in developed markets, there's still room for growth in emerging economies. The company's global network and diverse product portfolio make it well-suited to address the unique healthcare needs of these markets.

Sustainability Initiatives

With increasing focus on environmental sustainability in healthcare, B. Braun's efforts in this area could become a key differentiator. The company's commitment to sustainable practices not only aligns with global trends but also appeals to environmentally conscious healthcare providers and patients.

Key Takeaways

1. B. Braun's diverse product portfolio and global presence position it as a leader in the pharmaceutical and medical device industry.
2. The company's focus on innovation, particularly in digitalization and IoMT, sets it apart from competitors.
3. Strategic investments in U.S. manufacturing and partnerships have strengthened B. Braun's market position.
4. Despite challenges like supply chain disruptions, B. Braun has shown resilience and continued growth.
5. Future opportunities in telehealth, emerging markets, and sustainability initiatives present promising avenues for further expansion.

FAQs

1. What is B. Braun's annual revenue? In 2023, B. Braun reported sales of €8.75 billion, representing a 3% increase from the previous year.

2. How many products does B. Braun offer? B. Braun has a portfolio of over 5,000 different healthcare products.

3. What percentage of B. Braun's products are manufactured in-house? B. Braun manufactures 95% of its products in-house.

4. In how many countries does B. Braun operate? B. Braun has offices and production facilities in more than 60 countries.

5. What is B. Braun's strategy for supply chain resilience? B. Braun has invested over $1 billion in North American manufacturing facilities and increased "safety stock" inventory levels to ensure supply chain resilience.

Sources cited: [1] https://en.wikipedia.org/wiki/B._Braun [3] https://www.swotandpestle.com/b-braun/ [7] https://www.bbraunusa.com/en/about-us/responsibility/supply-chain.html [9] https://www.bbraun.ie/en/about-us/company/facts-and-figures.html